Design of therapeutic vaccines: Hepatitis B as an example

Microbial Biotechnology

Volumn 5, Issue 2, 2012, Pages 270-282

  Kutscher, Sarah ^a   Bauer, Tanja ^a   Dembek, Claudia ^a   Sprinzl, Martin ^a   Protzer, Ulrike ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; HEPATITIS B VACCINE; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2;

ADAPTIVE IMMUNITY; ANTIVIRAL THERAPY; ARTICLE; DRUG DESIGN; DRUG HALF LIFE; DRUG TARGETING; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INNATE IMMUNITY; LIVER CANCER; LIVER DISEASE; NONHUMAN; PLASMA HALF LIFE;

HEPATITIS B VACCINES; HEPATITIS B, CHRONIC; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOTHERAPY;

EID: 84857196807     PISSN: 17517907     EISSN: 17517915     Source Type: Journal    
DOI: 10.1111/j.1751-7915.2011.00303.x     Document Type: Article

References (98)

1. Abken, H., Hombach, A., and Heuser, C. (2003) Immune response manipulation: recombinant immunoreceptors endow T-cells with predefined specificity. Curr Pharm Des 9: 1992-2001.
2. Addison, W.R., Walters, K.A., Wong, W.W., Wilson, J.S., Madej, D., Jewell, L.D., and Tyrrell, D.L. (2002) Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication. J Virol 76: 6356-6363.
3. Aguilar, J.C., Lobaina, Y., Muzio, V., Garcia, D., Penton, E., Iglesias, E., etal. (2004) Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen. Immunol Cell Biol 82: 539-546.
4. Akbar, S.M., Yoshida, O., Chen, S., Cesar, A.J., Abe, M., Matsuura, B., etal. (2010) Immune modulator and antiviral potential of dendritic cells pulsed with both hepatitis B surface antigen and core antigen for treating chronic HBV infection. Antivir Ther 15: 887-895.
5. Akbar, S.M.F., and Onji, M. (2005) Preventive and therapeutic approaches against hepatitis B virus by vaccine. Hep B Annual 2: 31-55.
6. Bachmann, M.F., and Jennings, G.T. (2010) Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 10: 787-796.
7. Bauer, T., Sprinzl, M., and Protzer, U. (2011) Immune control of hepatitis B virus. Dig Dis 29: 423-433.
8. Beckebaum, S., Cicinnati, V.R., and Gerken, G. (2002) DNA-based immunotherapy: potential for treatment of chronic viral hepatitis? Rev Med Virol 12: 297-319.
9. Berthoud, T.K., Hamill, M., Lillie, P.J., Hwenda, L., Collins, K.A., Ewer, K.J., etal. (2011) Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis 52: 1-7.
10. Betancourt, A.A., Delgado, C.A., Estevez, Z.C., Martinez, J.C., Rios, G.V., Aureoles-Rosello, S.R., etal. (2007) Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens. Int J Infect Dis 11: 394-401.
11. Bohne, F., Chmielewski, M., Ebert, G., Wiegmann, K., Kurschner, T., Schulze, A., etal. (2008) T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes. Gastroenterology 134: 239-247.
12. van Bommel, F., de Man, R.A., Wedemeyer, H., Deterding, K., Petersen, J., Buggisch, P., etal. (2010) Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 51: 73-80.
13. Boni, C., Bertoletti, A., Penna, A., Cavalli, A., Pilli, M., Urbani, S., etal. (1998) Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 102: 968-975.
14. Cavenaugh, J.S., Awi, D., Mendy, M., Hill, A.V., Whittle, H., and McConkey, S.J. (2011) Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection. PLoS ONE 6: e14626.
15. Chen, A., Ahlen, G., Brenndorfer, E.D., Brass, A., Holmstrom, F., Chen, M., etal. (2011) Heterologous T cells can help restore function in dysfunctional hepatitis C virus nonstructural 3/4A-specific T cells during therapeutic vaccination. J Immunol 186: 5107-5118.
16. Chen, C.J., Yang, H.I., Su, J., Jen, C.L., You, S.L., Lu, S.N., etal. (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295: 65-73.
17. Coffman, R.L., Sher, A., and Seder, R.A. (2010) Vaccine adjuvants: putting innate immunity to work. Immunity 33: 492-503.
18. Cornberg, M., Protzer, U., Dollinger, M.M., Petersen, J., Wedemeyer, H., Berg, T., etal. (2008) The German guideline for the management of hepatitis B virus infection: short version. J Viral Hepat 15 (Suppl. 1): 1-21.
19. Cornberg, M., Protzer, U., Petersen, J., Wedemeyer, H., Berg, T., Jilg, W., etal. (2011) [Prophylaxis, diagnosis and therapy of hepatitis B virus infection - the german guideline]. Z Gastroenterol 49: 871-930.
20. Cosma, A., Nagaraj, R., Buhler, S., Hinkula, J., Busch, D.H., Sutter, G., etal. (2003) Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 22: 21-29.
21. Crispe, I.N., Giannandrea, M., Klein, I., John, B., Sampson, B., and Wuensch, S. (2006) Cellular and molecular mechanisms of liver tolerance. Immunol Rev 213: 101-118.
22. Dahmen, A., Herzog-Hauff, S., Bocher, W.O., Galle, P.R., and Lohr, H.F. (2002) Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B. J Med Virol 66: 452-460.
23. Das, A., and Maini, M.K. (2010) Innate and adaptive immune responses in hepatitis B virus infection. Dig Dis 28: 126-132.
24. Das, A., Hoare, M., Davies, N., Lopes, A.R., Dunn, C., Kennedy, P.T., etal. (2008) Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J Exp Med 205: 2111-2124.
25. Dienstag, J.L., Stevens, C.E., Bhan, A.K., and Szmuness, W. (1982) Hepatitis B vaccine administered to chronic carriers of hepatitis B surface antigen. Ann Intern Med 96: 575-579.
26. Dunn, C., Peppa, D., Khanna, P., Nebbia, G., Jones, M., Brendish, N., etal. (2009) Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 137: 1289-1300.
27. Farag, M.M., Hoyler, B., Encke, J., Stremmel, W., and Weigand, K. (2010) Dendritic cells can effectively be pulsed by HBVsvp and induce specific immune reactions in mice. Vaccine 29: 200-206.
28. Finzi, D., Blankson, J., Siliciano, J.D., Margolick, J.B., Chadwick, K., Pierson, T., etal. (1999) Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5: 512-517.
29. Fisicaro, P., Valdatta, C., Massari, M., Loggi, E., Biasini, E., Sacchelli, L., etal. (2010) Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 138: 682-693.e4.
30. Ganem, D., and Prince, A.M. (2004) Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 350: 1118-1129.
31. Gehring, A.J., Xue, S.A., Ho, Z.Z., Teoh, D., Ruedl, C., Chia, A., etal. (2010) Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. J Hepatol 55: 103-110.
32. Gudmundsdotter, L., Sjodin, A., Bostrom, A.C., Hejdeman, B., Theve-Palm, R., Alaeus, A., etal. (2006) Therapeutic immunization for HIV. Springer Semin Immunopathol 28: 221-230.
33. Hawkins, R.E., Gilham, D.E., Debets, R., Eshhar, Z., Taylor, N., Abken, H., etal. (2010) Development of adoptive cell therapy for cancer: a clinical perspective. Hum Gene Ther 21: 665-672.
34. Heathcote, E.J., Marcellin, P., Buti, M., Gane, E., De Man, R.A., Krastev, Z., etal. (2011) Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 140: 132-143.
35. Heathcote, J., McHutchison, J., Lee, S., Tong, M., Benner, K., Minuk, G., etal. (1999) A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T cell vaccine study group. Hepatology 30: 531-536.
36. Heintges, T., Petry, W., Kaldewey, M., Erhardt, A., Wend, U.C., Gerlich, W.H., etal. (2001) Combination therapy of active HBsAg vaccination and interferon-alpha in interferon-alpha nonresponders with chronic hepatitis B. Dig Dis Sci 46: 901-906.
37. Hildesheim, A., Herrero, R., Wacholder, S., Rodriguez, A.C., Solomon, D., Bratti, M.C., etal. (2007) Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298: 743-753.
38. Hilleman, M.R. (2003) Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus. Vaccine 21: 4626-4649.
39. Hoofnagle, J.H., Doo, E., Liang, T.J., Fleischer, R., and Lok, A.S. (2007) Management of hepatitis B: summary of a clinical research workshop. Hepatology 45: 1056-1075.
40. Horiike, N., Fazle Akbar, S.M., Michitaka, K., Joukou, K., Yamamoto, K., Kojima, N., etal. (2005) In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B. J Clin Virol 32: 156-161.
41. Hui, C.K., Lie, A., Au, W.Y., Leung, Y.H., Ma, S.Y., Cheung, W.W., etal. (2005) A long-term follow-up study on hepatitis B surface antigen-positive patients undergoing allogeneic hematopoietic stem cell transplantation. Blood 106: 464-469.
42. Im, S.J., Yang, S.H., Yoon, S.K., and Sung, Y.C. (2009) Increase of plasma IL-12/p40 ratio induced by the combined therapy of DNA vaccine and lamivudine correlates with sustained viremia control in CHB carriers. Immune Netw 9: 20-26.
43. Janetzki, S., Britten, C.M., Kalos, M., Levitsky, H.I., Maecker, H.T., Melief, C.J., etal. (2009) 'MIATA'-minimal information about T cell assays. Immunity 31: 527-528.
44. June, C.H. (2007) Principles of adoptive T cell cancer therapy. J Clin Invest 117: 1204-1212.
45. Kakimi, K., Isogawa, M., Chung, J., Sette, A., and Chisari, F.V. (2002) Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections. J Virol 76: 8609-8620.
46. Knolle, P.A., and Gerken, G. (2000) Local control of the immune response in the liver. Immunol Rev 174: 21-34.
47. Kosinska, A.D., Zhang, E., Lu, M., and Roggendorf, M. (2010) Therapeutic vaccination in chronic hepatitis B: preclinical studies in the woodchuck. Hepat Res Treat 2010: 817580.
48. Kutscher, S., Allgayer, S., Dembek, C.J., Bogner, J.R., Protzer, U., Goebel, F.D., etal. (2010) MVA-nef induces HIV-1-specific polyfunctional and proliferative T-cell responses revealed by the combination of short- and long-term immune assays. Gene Ther 17: 1372-1383.
49. Kwon, H., and Lok, A.S. (2011) Hepatitis B therapy. Nat Rev Gastroenterol Hepatol 8: 275-284.
50. Lazdina, U., Cao, T., Steinbergs, J., Alheim, M., Pumpens, P., Peterson, D.L., etal. (2001) Molecular basis for the interaction of the hepatitis B virus core antigen with the surface immunoglobulin receptor on naive B cells. J Virol 75: 6367-6374.
51. Levrero, M., Pollicino, T., Petersen, J., Belloni, L., Raimondo, G., and Dandri, M. (2009) Control of cccDNA function in hepatitis B virus infection. J Hepatol 51: 581-592.
52. Liu, M.A. (2011) DNA vaccines: an historical perspective and view to the future. Immunol Rev 239: 62-84.
53. Loomba, R., and Liang, T.J. (2006) Novel approaches to new therapies for hepatitis B virus infection. Antivir Ther 11: 1-15.
54. Luo, J., Li, J., Chen, R.L., Nie, L., Huang, J., Liu, Z.W., etal. (2010) Autologus dendritic cell vaccine for chronic hepatitis B carriers: a pilot, open label, clinical trial in human volunteers. Vaccine 28: 2497-2504.
55. McMahon, B.J. (2009) The natural history of chronic hepatitis B virus infection. Hepatology 49: S45-S55.
56. Mancini-Bourgine, M., Fontaine, H., Scott-Algara, D., Pol, S., Brechot, C., and Michel, M.L. (2004) Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology 40: 874-882.
57. Manigold, T., and Racanelli, V. (2007) T-cell regulation by CD4 regulatory T cells during hepatitis B and C virus infections: facts and controversies. Lancet Infect Dis 7: 804-813.
58. Manns, M.P., Foster, G.R., Rockstroh, J.K., Zeuzem, S., Zoulim, F., and Houghton, M. (2007) The way forward in HCV treatment - finding the right path. Nat Rev Drug Discov 6: 991-1000.
59. Marcellin, P., Bonino, F., Lau, G.K., Farci, P., Yurdaydin, C., Piratvisuth, T., etal. (2009) Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 136: 2169-2179.e4.
60. Mayr, A., Stickl, H., Muller, H.K., Danner, K., and Singer, H. (1978) [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism]. Zentralbl Bakteriol B 167: 375-390. (author's transl.)
61. Menne, S., Roneker, C.A., Korba, B.E., Gerin, J.L., Tennant, B.C., and Cote, P.J. (2002) Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-l-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection. J Virol 76: 5305-5314.
62. Michel, M.L., Deng, Q., and Mancini-Bourgine, M. (2011) Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. J Hepatol 54: 1286-1296.
63. Milich, D.R., Thornton, G.B., Neurath, A.R., Kent, S.B., Michel, M.L., Tiollais, P., and Chisari, F.V. (1985) Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science 228: 1195-1199.
64. Milich, D.R., Chen, M., Schodel, F., Peterson, D.L., Jones, J.E., and Hughes, J.L. (1997) Role of B cells in antigen presentation of the hepatitis B core. Proc Natl Acad Sci USA 94: 14648-14653.
65. Moucari, R., Korevaar, A., Lada, O., Martinot-Peignoux, M., Boyer, N., Mackiewicz, V., etal. (2009) High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol 50: 1084-1092.
66. Munir, S., Saleem, S., Idrees, M., Tariq, A., Butt, S., Rauff, B., etal. (2010) Hepatitis C treatment: current and future perspectives. Virol J 7: 296.
67. Pancholi, P., Lee, D.H., Liu, Q., Tackney, C., Taylor, P., Perkus, M., etal. (2001) DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee. Hepatology 33: 448-454.
68. Paris, R.M., Kim, J.H., Robb, M.L., and Michael, N.L. (2010) Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. Expert Rev Vaccines 9: 1055-1069.
69. Protzer, U., and Abken, H. (2010) Can engineered 'designer' T cells outsmart chronic hepatitis B? Hepat Res Treat 2010: 901216.
70. Rehermann, B., and Nascimbeni, M. (2005) Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 5: 215-229.
71. Riddell, S.R., and Protzer, U. (2010) Carving the CAR. Gene Ther 17: 1191-1192.
72. Roggendorf, M., Yang, D., and Lu, M. (2010) The woodchuck: a model for therapeutic vaccination against hepadnaviral infection. Pathol Biol (Paris) 58: 308-314.
73. Rouse, B.T., and Sehrawat, S. (2010) Immunity and immunopathology to viruses: what decides the outcome? Nat Rev Immunol 10: 514-526.
74. Schirmbeck, R., Dikopoulos, N., Kwissa, M., Leithauser, F., Lamberth, K., Buus, S., etal. (2003) Breaking tolerance in hepatitis B surface antigen (HBsAg) transgenic mice by vaccination with cross-reactive, natural HBsAg variants. Eur J Immunol 33: 3342-3352.
75. Schumann, A., Fiedler, M., Dahmen, U., Grosse-Wilde, H., Roggendorf, M., and Lindemann, M. (2007) Cellular and humoral immune response to a third generation hepatitis B vaccine. J Viral Hepat 14: 592-598.
76. Seder, R.A., Darrah, P.A., and Roederer, M. (2008) T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 8: 247-258.
77. Stoop, J.N., van der Molen, R.G., Baan, C.C., van der Laan, L.J., Kuipers, E.J., Kusters, J.G., and Janssen, H.L. (2005) Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 41: 771-778.
78. Storni, T., Ruedl, C., Schwarz, K., Schwendener, R.A., Renner, W.A., and Bachmann, M.F. (2004) Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol 172: 1777-1785.
79. Sutter, G., and Moss, B. (1992) Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA 89: 10847-10851.
80. Tang, T.J., Kwekkeboom, J., Mancham, S., Binda, R.S., de Man, R.A., Schalm, S.W., etal. (2005) Intrahepatic CD8+ T-lymphocyte response is important for therapy-induced viral clearance in chronic hepatitis B infection. J Hepatol 43: 45-52.
81. Thimme, R., Wieland, S., Steiger, C., Ghrayeb, J., Reimann, K.A., Purcell, R.H., and Chisari, F.V. (2003) CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 77: 68-76.
82. Thomson, A.W., and Knolle, P.A. (2010) Antigen-presenting cell function in the tolerogenic liver environment. Nat Rev Immunol 10: 753-766.
83. Ueno, H., Schmitt, N., Klechevsky, E., Pedroza-Gonzalez, A., Matsui, T., Zurawski, G., etal. (2010) Harnessing human dendritic cell subsets for medicine. Immunol Rev 234: 199-212.
84. Vandepapeliere, P., Lau, G.K., Leroux-Roels, G., Horsmans, Y., Gane, E., Tawandee, T., etal. (2007) Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 25: 8585-8597.
85. Vandepapeliere, P., Horsmans, Y., Moris, P., Van Mechelen, M., Janssens, M., Koutsoukos, M., etal. (2008) Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 26: 1375-1386.
86. Virgin, H.W., Wherry, E.J., and Ahmed, R. (2009) Redefining chronic viral infection. Cell 138: 30-50.
87. Vitiello, A., Ishioka, G., Grey, H.M., Rose, R., Farness, P., LaFond, R., etal. (1995) Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest 95: 341-349.
88. Wang, F.S., and Zhang, Z. (2009) Host immunity influences disease progression and antiviral efficacy in humans infected with hepatitis B virus. Expert Rev Gastroenterol Hepatol 3: 499-512.
89. Webster, G.J., Reignat, S., Maini, M.K., Whalley, S.A., Ogg, G.S., King, A., etal. (2000) Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology 32: 1117-1124.
90. Webster, G.J., Reignat, S., Brown, D., Ogg, G.S., Jones, L., Seneviratne, S.L., etal. (2004) Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 78: 5707-5719.
91. Wieland, S.F., Spangenberg, H.C., Thimme, R., Purcell, R.H., and Chisari, F.V. (2004) Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees. Proc Natl Acad Sci USA 101: 2129-2134.
92. Woodland, D.L. (2004) Jump-starting the immune system: prime-boosting comes of age. Trends Immunol 25: 98-104.
93. Wu, J., Lu, M., Meng, Z., Trippler, M., Broering, R., Szczeponek, A., etal. (2007) Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology 46: 1769-1778.
94. Xu, D.Z., Zhao, K., Guo, L.M., Li, L.J., Xie, Q., Ren, H., etal. (2008) A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS ONE 3: e2565.
95. Yalcin, K., Danis, R., Degertekin, H., Alp, M.N., Tekes, S., and Budak, T. (2003) The lack of effect of therapeutic vaccination with a pre-S2/S HBV vaccine in the immune tolerant phase of chronic HBV infection. J Clin Gastroenterol 37: 330-335.
96. Yang, S.H., Lee, C.G., Park, S.H., Im, S.J., Kim, Y.M., Son, J.M., etal. (2006) Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. Gene Ther 13: 1110-1117.
97. Zhang, Y.Y., Zhang, B.H., Theele, D., Litwin, S., Toll, E., and Summers, J. (2003) Single-cell analysis of covalently closed circular DNA copy numbers in a hepadnavirus-infected liver. Proc Natl Acad Sci USA 100: 12372-12377.
98. Zhu, Y., Yamamoto, T., Cullen, J., Saputelli, J., Aldrich, C.E., Miller, D.S., etal. (2001) Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol 75: 311-322.